Last reviewed · How we verify
Antagonist GnRH Cetrotide
Cetrotide is a GnRH antagonist that directly blocks gonadotropin-releasing hormone receptors to suppress luteinizing hormone and follicle-stimulating hormone secretion.
Cetrotide is a GnRH antagonist that directly blocks gonadotropin-releasing hormone receptors to suppress luteinizing hormone and follicle-stimulating hormone secretion. Used for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (in vitro fertilization).
At a glance
| Generic name | Antagonist GnRH Cetrotide |
|---|---|
| Sponsor | Instituto Valenciano de Infertilidad, IVI VALENCIA |
| Drug class | GnRH antagonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
By competitively antagonizing GnRH receptors in the pituitary gland, cetrotide rapidly suppresses the release of LH and FSH without an initial flare effect. This prevents premature ovulation during controlled ovarian hyperstimulation in assisted reproductive technology cycles, allowing precise timing of oocyte retrieval.
Approved indications
- Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (in vitro fertilization)
Common side effects
- Headache
- Ovarian hyperstimulation syndrome (OHSS)
- Abdominal pain/discomfort
- Nausea
- Injection site reactions
Key clinical trials
- PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study) (NA)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A (PHASE3)
- NATural Ovarian Stimulation (PHASE4)
- Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF (NA)
- Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF (NA)
- Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A (PHASE3)
- PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: